HOME
ABOUT
Overview
Purpose &Values
Board of Directors/Leadership/SAB
Investors and Partners
PIPELINE
Pipeline
Atrasentan
BION-1301
Publications
Partnering Opportunities
MEDIA
CAREERS
CONTACT US
简体中文
HOME
ABOUT
Overview
Purpose &Values
Board of Directors/Leadership/SAB
Investors and Partners
PIPELINE
Pipeline
Atrasentan
BION-1301
Publications
Partnering Opportunities
MEDIA
CAREERS
CONTACT US
Pipeline
Atrasentan
BION-1301
Publications
Partnering Opportunities
Location :
Home
>
Publications
PUBLICATIONS
15
2022-06
Atrasentan for the Treatment of IgA Nephropathy: Interim Results from the AFFINITY Study
59th ERA Congress 2022 | May 2022
05
2022-05
A Systems Nephrology Framework for the Molecular Classification of Chronic Kidney Disease
59th ERA Congress 2022 | May 2022
04
2022-05
Updated Interim Results of a Phase I/II Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of BION-1301 in Patients with IgA Nephropathy
59th ERA Congress 2022 | May 2022
04
2022-05
Selective Endothelin A Receptor Antagonist Atrasentan Attenuates Mesangial Cell Injury, Proteinuria and Intra-Renal Proliferative, Inflammatory and Fibrotic Transcriptional Networks in a Rat Model of Mesangioproliferative Glomerulonephritis
59th ERA Congress 2022 | May 2022
04
2022-05
A Phase I/II, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults with IgA Nephropathy
59th ERA Congress 2022 | May 2022
<
1
>